Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: A meta-analysis of randomized trials

Nursing and Health Professions

• Heart Failure 100%
• Carvedilol 100%
• Chronic Kidney Failure 90%
• Confidence Interval 60%
• Patient 60%
• Hospitalization 40%
• Combination Therapy 40%
• Cardiovascular Mortality 40%
• Inpatient 40%
• Dialysis 30%
• All Cause Mortality 20%
• Systolic Heart Failure 20%
• Kidney Disease 20%
• Estimated Glomerular Filtration Rate 20%
• Sudden Cardiac Death 20%
• Placebo 20%
• Survival 20%
• Mortality 20%
• Adult 20%
• Meta Analysis 10%
• Group Therapy 10%
• Creatinine Blood Level 10%
• Post Hoc Analysis 10%
• Patient Coding 10%
• Sensitivity Analysis 10%
• Electrolyte 10%
• Left Ventricular Systolic Dysfunction 10%
• Heart Left Ventricle Failure 10%
• Control 10%
• Procedures 10%
• Symptom 10%
• Incidence 10%
• Analysis 10%

Medicine and Dentistry

• Heart Failure 100%
• Carvedilol 100%
• Chronic Kidney Disease 90%
• Hazard Ratio 60%
• Combination Therapy 40%
• Cardiovascular Mortality 40%
• Therapeutic Procedure 30%
• Nephropathy 20%
• All Cause Mortality 20%
• Sudden Cardiac Death 20%
• Systolic Heart Failure 20%
• Mortality 20%
• Survival 20%
• Group Therapy 10%
• Meta-Analysis 10%
• Post-Hoc Analysis 10%
• Electrolyte 10%
• Left Ventricular Systolic Dysfunction 10%
• Heart Left Ventricle Failure 10%
• Sensitivity Analysis 10%
• Diet 10%
• Symptom 10%
• Analysis 10%
• Arm 10%
• Incidence 10%
• Heart 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Heart Failure 100%
• Carvedilol 100%
• Chronic Kidney Failure 90%
• Cardiovascular Mortality 40%
• Dialysis 30%
• Kidney Disease 20%
• All Cause Mortality 20%
• Mortality 20%
• Survival 20%
• Sudden Cardiac Death 20%
• Randomized Controlled Trial 20%
• Systolic Heart Failure 20%
• Electrolyte 10%
• Heart Left Ventricle Failure 10%
• Incidence 10%
• Symptom 10%
• Left Ventricular Systolic Dysfunction 10%